News | May 13, 2015

Cancer Targeted Technology Receives $2 Million Grant for PET Prostate Imaging Trials

New PET biomarker designed to bond with prostate-specific membrane antigen on prostate cancer cells

May 13, 2015 — Cancer Targeted Technology (CTT), announced that it was awarded a NIH two-year, $2 million Small Business Innovation Research (SBIR) grant. The funds will be used to develop a new agent that will help diagnose and monitor metastatic prostate cancer.

CTT1057 — a positron emission tomography (PET) imaging agent discovered by Cliff Berkman, Ph.D., professor of chemistry at Washington State University and CTT chief scientific officer — may be well-suited for imaging the location of cancer metastases that have escaped the prostate gland. Unlike other prostate cancer targeting agents, CTT1057 is a small molecule that homes and binds irreversibly to prostate-specific membrane antigen (PSMA) that is overexpressed on prostate cancer.

Berkman commented, “Our team has spent several years carefully developing and optimizing CTT1057; as the lead scientist on this program I am excited that this SBIR grant will allow CTT to translate these significant research findings into human clinical studies.”

CTT1057 was designed as an ideal delivery vehicle and can be loaded with a variety of radionuclides and chemotherapies to specifically and safely guide imaging nuclides and therapies to PSMA-expressing prostate cancer. In 2014, CTT received a grant from the Washington state Life Sciences Discovery Fund to perform manufacturing and key preclinical studies for CTT1057. The current SBIR allows CTT to continue the manufacturing and file the Investigational New Drug Application for the human clinical trial in prostate cancer, set to commence in late 2015. CTT will work with contractors and collaborator Henry VanBrocklin, Ph.D., professor, Department of Radiology and Biomedical Imaging, and clinicians at University of California-San Francisco, to conduct initial clinical trials with 18F-labeled CTT1057.

VanBrocklin added: "We are eager to continue our collaboration with CTT to advance CTT1057 to human trials. We believe this important agent will improve the availability and efficacy of imaging for prostate cancer diagnosis, staging and treatment monitoring."

For more information: www.cancertargetedtechnology.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...